Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Underwriting syndicate comprised of Goldman, Sachs & Co., Morgan Stanley Dean Witter, BT Alex Brown, Dain Rauscher Wessels, J. P. Morgan Securities and Piper Jaffray commence Aug. 27 public offering of 12.5 mil. shares of Medtronic common stock (plus an over-allotment option of 1.875 mil. shares), the firm reports. Based on Medtronic closing price on Aug. 28 of 56-5/8, the offering is valued at approximately $707.8 mil. Completion of the offering is required in order for Medtronic to purchase through a pooling transaction external defibrillator firm Physio-Control. The $538 mil. stock-swap merger is expected to close in the fall despite recent requests for additional information from the Federal Trade Commission ("The Gray Sheet" Aug. 17, In Brief). Medtronic/Avecor:. FTC requests additional information in connection with its review of the firms' proposed merger, announced in July ("The Gray Sheet" July 20, p. 3)

You may also be interested in...

Latest UK COVID-19 Specification: For Rapidly Manufactured CPAP Systems

Following hot on the heels of its Rapidly Manufactured Ventilator Specification document, the UK’s regulator has issued another speedy regulatory permit for fast production of respiratory assist devices.

Podcast: Biopharma's Moment To Deliver On Coronavirus And The People's Hope

Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.

Hengrui Quickly Fills Celgene Void Amid Nationalism Surge In China

China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts